BMS Hopes Turning Point Buyout Will Fare Better Than Roche’s Ignyta Acquisition

 
• By Joseph Haas
Bristol Myers Squibb
Bristol Myers Squibb makes big precision oncology play in Turning Point buyout • Source: Bristol Myers Squibb (ROBERT BRUSCHINI IM GES LLC)

More from Deals

More from Business